CLOSE-3NCT05724446
Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
At risk: Primary completion moved at least 6 years 10 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Dec 31, 2025 to Nov 18, 2032 Show 6 more changesShow less
- Eligibility criteria expanded, about 25 words
- Trial status changed: Unknown → Recruiting
- Study completion pushed from Dec 31, 2025 to Dec 31, 2032
- Start date pushed from Dec 12, 2022 to Jan 4, 2023
- Secondary endpoints: details revised at 2 of 2 entries
- Site details revised
- Minor Changed Registry marked status Unknown; last known: Recruiting
- Notable Primary and study completion dates: Aug 31, 2024 to Dec 31, 2025
- Secondary endpoints: details revised at 1 of 2 entries
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Assess the safety of Clobetasol propionate ophthalmic nanoemulsion, 0.05% treatment after cataract surgery in pediatric population 0 to 3 years of age, compared to Prednisolone acetate ophthalmic suspension, 1%.
Timeframe: Day 43
Secondary (2)
Assess the efficacy on ocular inflammation of Clobetasol propionate ophthalmic nanoemulsion, 0.05% treatment after cataract surgery in pediatric population 0 to 3 years of age, compared to Prednisolone acetate ophthalmic suspension, 1%.
Assess the efficacy on pain of Clobetasol propionate ophthalmic nanoemulsion, 0.05% treatment after cataract surgery in pediatric population 0 to 3 years of age, compared to Prednisolone acetate ophthalmic suspension, 1%.
Arms and interventions
Clobetasol propionateExperimental
One drop of Clobetasol propionate ophthalmic nanoemulsion, 0.05% will be administered of the study eye QID beginning the day after surgery (Day 1) for 14 days followed by a tapering period of 14 days.
Prednisolone acetateActive comparator
One drop of Prednisolone ophthalmic suspension, 1% will be administered of the study eye QID beginning the day after surgery (Day 1) for 14 days followed by a tapering period of 14 days.
Drugs: Clobetasol Propionate, Prednisolone acetate ophthalmic suspension, 1%
Sites
1 site in 1 country
- Hospìtal Sant Joan de DeuBarcelona, Barcelone, Spain